Published in Eur Arch Otorhinolaryngol on September 09, 2010
A quantitative histomorphometric classifier (QuHbIC) identifies aggressive versus indolent p16-positive oropharyngeal squamous cell carcinoma. Am J Surg Pathol (2014) 0.95
Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: implications for treatment. Otolaryngol Clin North Am (2013) 0.94
Caveolin 1 (Cav-1) and actin-related protein 2/3 complex, subunit 1B (ARPC1B) expressions as prognostic indicators for oral squamous cell carcinoma (OSCC). Eur Arch Otorhinolaryngol (2015) 0.76
Discovery of specific ligands for oral squamous carcinoma to develop anti-cancer drug loaded precise targeting nanotherapeutics. J Calif Dent Assoc (2012) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
p21 is a universal inhibitor of cyclin kinases. Nature (1993) 15.55
The p53 tumour suppressor gene. Nature (1991) 14.49
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev (1995) 13.66
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
The role of STATs in transcriptional control and their impact on cellular function. Oncogene (2000) 6.42
The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med (1997) 6.41
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (1996) 6.11
Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta (1994) 5.81
Validating survivin as a cancer therapeutic target. Nat Rev Cancer (2003) 5.73
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
Programmed cell death: apoptosis and oncogenesis. Cell (1991) 4.78
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol (2003) 4.05
Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer (2007) 3.98
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol (2007) 3.88
Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer (2005) 3.79
Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer (2005) 3.72
Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol (2004) 3.64
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Oncogenic mutations of PIK3CA in human cancers. Cell Cycle (2004) 3.47
Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer (2005) 3.27
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res (2002) 2.96
Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer (2007) 2.75
The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Res (2005) 2.74
Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol (2004) 2.59
Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res (2009) 2.55
Nucleotide excision repair. II: From yeast to mammals. Trends Genet (1993) 2.50
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res (2002) 2.41
Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res (2005) 2.32
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer (1998) 2.29
Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res (1994) 2.28
Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol (2003) 2.26
A causal role for human papillomavirus in head and neck cancer. Lancet (2004) 2.21
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell (2006) 2.13
Focus on head and neck cancer. Cancer Cell (2004) 2.11
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 2.06
The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun (2004) 2.05
STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther (2006) 1.96
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer (2007) 1.80
Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res (1992) 1.70
Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res (1998) 1.63
Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer (2005) 1.52
Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck (1999) 1.44
Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck (2001) 1.44
ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res (2005) 1.41
Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer (2009) 1.41
p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol (2000) 1.39
Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res (2009) 1.36
Telomerase and human tumorigenesis. Semin Cancer Biol (2000) 1.33
Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene (2003) 1.32
Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev (2005) 1.31
P21 Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis. Mod Pathol (2009) 1.29
STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol (1999) 1.24
The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc (2001) 1.24
Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol (2000) 1.19
Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Adv Otorhinolaryngol (2005) 1.16
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer (2007) 1.14
Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol (1997) 1.13
Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol (1999) 1.13
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer (2008) 1.11
Human papillomaviruses in head and neck carcinomas. N Engl J Med (2007) 1.10
Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral Oncol (2003) 1.09
Human papillomavirus-positive tonsillar carcinomas: a different tumor entity? Med Microbiol Immunol (2002) 1.08
Cyclin D1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma. Oral Oncol (2000) 1.07
Reduced E-cadherin expression is an indicator of unfavourable prognosis in oral squamous cell carcinoma. Oral Oncol (2005) 1.06
Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer (2002) 1.06
Laryngeal preservation in head and neck cancer: multidisciplinary approach. Lancet Oncol (2006) 1.02
p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res (2001) 1.00
Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in oral squamous cell carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation. Med Oral Patol Oral Cir Bucal (2009) 1.00
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol (2009) 1.00
Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. Oncol Rep (2007) 0.98
Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. J Gen Virol (2006) 0.96
Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck (2007) 0.96
Expression of Bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. Oral Oncol (2008) 0.94
Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors. J Gastrointest Surg (2009) 0.94
Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res (1997) 0.93
Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol (2007) 0.93
p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol (1993) 0.93
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res (2002) 2.96
Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88
Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res (2004) 1.70
High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia (2008) 1.56
High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res (2005) 1.46
Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res (2006) 1.39
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia (2010) 1.37
Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res (2004) 1.24
Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics (2007) 1.23
A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res (2009) 1.23
Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res (2006) 1.18
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer (2004) 1.16
High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res (2004) 1.14
Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery (2005) 1.11
Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res (2003) 1.10
Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep (2007) 1.05
Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer. Prostate (2008) 1.04
Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol (2010) 1.02
Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg (2002) 1.01
Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 1.01
DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer (2006) 1.01
The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2005) 1.00
Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg (2005) 1.00
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med (2008) 1.00
Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. Arch Surg (2007) 0.98
Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg (2003) 0.98
A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Oncogene (2004) 0.97
Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis. Carcinogenesis (2004) 0.96
Association between Cyclooxygenase expression and colorectal adenoma characteristics. Cancer Res (2003) 0.94
5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. Int J Cancer (2006) 0.93
Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate (2009) 0.93
Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity. Jpn J Cancer Res (2002) 0.92
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett (2005) 0.92
Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer. J Oncol (2009) 0.92
Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma. J Gastrointest Surg (2002) 0.91
Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res (2005) 0.91
Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch Surg (2006) 0.90
High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. J Gastrointest Surg (2008) 0.90
The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate (2010) 0.89
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer. BMC Cancer (2008) 0.89
High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chemother Pharmacol (2008) 0.88
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res (2003) 0.87
Thymidylate synthase polymorphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients. Int J Oncol (2008) 0.87
Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J Gastrointest Surg (2004) 0.85
EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma. PLoS One (2013) 0.84
Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis. Int J Oncol (2009) 0.84
Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate (2006) 0.83
Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer. Arch Surg (2007) 0.83
Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer. Clin Lung Cancer (2010) 0.82
Inhibition of pre-mRNA splicing by cisplatin and platinum analogs. Int J Oncol (2003) 0.82
Expression and clinical significance of methylenetetrahydrofolate reductase in patients with colorectal cancer. Clin Colorectal Cancer (2006) 0.82
Towards the molecular characterization of disease: comparison of molecular and histological analysis of esophageal epithelia. J Gastrointest Surg (2007) 0.81
Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer (2006) 0.81
Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer (2006) 0.81
Glutathione S-transferase PI (GST-PI) mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC. Lung Cancer (2012) 0.80
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int J Oncol (2007) 0.80
Role of retinoid X receptor mRNA expression in Barrett's esophagus. J Gastrointest Surg (2004) 0.80
Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. Int J Oncol (2008) 0.80
Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. Int J Oncol (2005) 0.79
Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study. Cell Oncol (Dordr) (2013) 0.79
The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res (2002) 0.79
Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases. Cancer Chemother Pharmacol (2009) 0.79
Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2. Int J Cancer (2006) 0.79
Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Anticancer Res (2008) 0.78
Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol (2006) 0.78
Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells. Anticancer Drugs (2002) 0.77
Quantitative determination of p16 gene expression by RT-PCR. Methods Mol Biol (2004) 0.77
Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer. Clin Lung Cancer (2010) 0.76
Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis. Ann Surg Oncol (2008) 0.76
Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine. Clin Colorectal Cancer (2007) 0.76
The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC). Lung Cancer (2010) 0.76
Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer. Clin Lung Cancer (2006) 0.76
Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences. BMC Cancer (2009) 0.75
Relative gene expression in normal and tumor tissue by quantitative RT-PCR. Methods Mol Biol (2002) 0.75